Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies

Pre-clinically, the mTORC1/2 inhibitor sapanisertib restored sensitivity to platinums and enhanced paclitaxel-induced cancer cell killing. NCT03430882 enrolled patients with mTOR pathway aberrant tumors to receive sapanisertib, carboplatin and paclitaxel. Primary objective was safety and secondary o...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhalabi, Omar, Groisberg, Roman, Zinner, Ralph, Hahn, Andrew W., Naing, Aung, Zhang, Shizhen, Tsimberidou, Apostolia M., Rodon, Jordi, Fu, Siqing, Yap, Timothy A., Hong, David S., Sun, Ming, Jiang, Yunfang, Pant, Shubham, Shah, Amishi Y., Zurita, Amado, Tannir, Nizar M., Vikram, Raghunandan, Roszik, Jason, Meric-Bernstam, Funda, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113233/
https://www.ncbi.nlm.nih.gov/pubmed/37072571
http://dx.doi.org/10.1038/s41698-023-00369-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113233/
https://www.ncbi.nlm.nih.gov/pubmed/37072571
http://dx.doi.org/10.1038/s41698-023-00369-w

Ejemplares similares